Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study

Table 2 Change from baseline in SpO₂/FiO₂ ratio (efficacy population)

Parameter	Visit	Placebo (N = 20)	Eclitasertib 600 mg (N = 47)
Change from baseline in SpO₂/FiO₂ ratio	Day 02	49.91 (− 24.29 to 124.12)	72.02 (− 1.53 to 145.56)
	Day 03	82.04 (5.68 to 158.39)	97.90 (23.35 to 172.45)
	Day 04	84.91 (5.95 to 163.87)	104.61 (28.83 to 180.39)
	Day 05	102.55 (23.28 to 181.82)	121.79 (45.87 to 197.72)
	Day 06	105.95 (26.73 to 185.18)	134.66 (58.76 to 210.57)
	Day 07	116.97 (36.66 to 197.29)	142.21 (65.78 to 218.63)
	Day 15	150.78 (71.65 to 229.90)	174.65 (98.79 to 250.51)
	Eclitasertib vs. placebo on Day 07	25.24 (− 21.54 to 72.01)

N: Number of patients; SpO₂/FiO₂: Peripheral oxygen saturation/Fraction of inspired oxygen
Values are point estimates of the mean absolute change from baseline in SpO₂/FiO₂ ratio (90% CI). A positive value in the change indicates a larger ratio at the day of measurement than at baseline

ISSN: 1465-993X